Velázquez-Sánchez-de-Cima S, Zamora-Ortiz G, Ruiz-Delgado GJ, Ruiz-Argüelles GJ

Language: English
References: 18
Page: 3-8
PDF size: 694.20 Kb.

ABSTRACT

Being hematopoietic stem cell transplantation a procedure with a higher risk of morbidity and mortality in older patients, many institutions place a limit of 50 to 55 years for HSCT. With better supportive care the ability to perform transplants successfully in older patients has steadily improved; however, age continues to have a significant impact. In a single institution along a 20-year period, 284 patients were grafted (130 autografts and 154 allografts. In autografted patients above (n = 30) or below (n = 100) 60 years of age, the overall survival (OS) was 67% at 180 months and 58% at 229 months respectively, whereas the median OS has not been reached in any groups, being above 180 and 229 months respectively (p NS), whereas in allografts, in patients above (n = 8) or below (n = 146) 60 years of age, the OS was 50% at 138 months and 38% at 155 months respectively, whereas the median OS was 60 and 20 months respectively (p NS). We conclude that grafting 38 individuals aged 60 years or more (30 autografts and 8 allografts), we have found that the long term-results are similar to those obtained in individuals younger than 60 years.

REFERENCES

1. Du W, Dansey R, Abella EM, Baynes R, Peters WP, Klein J, Akhtar A, Cherednikova L, Karanes C.: Successful allogeneic bone marrow transplantation in selected patients over 50 years of age: A single institution’s experience. Bone Marrow Transplant. 1998 May;21(10):1043-7.

2. Negrin RS, Blume KG.: Principles of hematopoietic cell transplantation. In Lichtman MA, Beutler E. Kipps TJ, Seligsohn U, Kaushansky K, Prchal JT.: Williams Hematology. 7th Ed. Mc Graw Hill. New York 2006. pp. 300-322

3. Ruiz-Delgado GJ, Ruiz-Argüelles GJ: A Mexican way to cope with stem cell transplantation. Hematology 2012, 17 (Suppl 1): 195-7

4. Charlson M, Pompei P, Ales KL, McKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987; 40:373-83.

5. Kessinger A, Armitage JO, Landmark JD, Smith DM, Weisenburger DD.: Autologous peripheral hematopoietic stem cell transplantation restores hemopoietic function following marrow ablative therapy. Blood 1988; 71: 723-727.

6. Ruiz-Argüelles A.: Flow cytometry in the clinical laboratory. Principles, applications and problems. Ann Biol Clin 1992; 50:735-743.

7. Gómez-Almaguer D, Ruiz-Argüelles GJ, Ruiz-Argüelles A, González-Llano O, Cantú OE, Hernández NE.: Hematopoietic stem cell allografts using a non-myeloablative conditioning regimen can be safely performed on an outpatient basis. Bone Marrow Transpl 2000; 25:131-133.

8. Ruiz-Argüelles A, Orfao A.: Caracterización y evaluación de células totipotenciales en sangre periférica y médula ósea. In Ruiz-Argüelles GJ, San-Miguel JF (editors): Actualización en Leucemias. Editorial Médica Panamericana. México City 1996. pp 79-82

9. Pinkel D, Straume T, Gray JW.: Cytogenetic analysis using quantitative, high sensitivity fluorescence hybridization. Proc Natl Acad Sci USA. 1996: 83:2934-2938.

10. Yam P, Petz L, Knowlton R, et al.: Use of DNA restriction fragment length polymorphisms to document marrow engraftment and mixed hematopoietic chimerism following bone marrow transplantation. Transplantation 1987;43:399-407.

11. Kaplan EL, Meier P.: Nonparametric estimations from incomplete observations. J Am Stat Assoc 1958; 53:457-63.

12. Solano-Genesta, Tarín-Arzaga, Cantú-Rodriguez OG, Gutiérrez-Aguirre CH, Martínez-Hernández RA, Cuervo-Sierra J, Gómez-Almaguer D.: Trasplante alogénico de células tallo con acondicionamiento de intensidad reducida en pacientes de edad avanzada, el método mexicano. Experiencia de un centro hospitalario del noreste de México. Rev Hematol Méx 2010; 11: 188-192.

13. Alyea EP, Kim HT, Ho V, Cutler C, et al. Comparative outcome of nonmyeloablative and myeloablative allogenic hematopoietic cell transplantation for patients older than 50 years of age. Blood 2005;105:1810-1814.

14. Falda M, Busca A, Baldi I, Mordini N, et al. Nonmyeloablative allogenic stem cell transplantation in elderly patients with hematological malignancies: results from the GITMO (Gruppo Italiano Trapianto Midollo Osseo) multicenter prospective clinical trial. Am J Hematol 2007;82:863-866.

15. Shimoni A, Kröger N, Zabelina T, Ayuk F, et al. Hematopoietic stem cell transplantation from unrelated donors in elderly patients (age › 55 years) with hematologic malignancies: older age is no longer a contraindication when using reduced intensity conditioning. Leukemia 2005;19:7-12.

16. Tsirigotis P, Bitan RO, Resnick IB, Samuel S, et al. A non myeloablative conditioning regimen in allogenic stem cell transplantation from related and unrelated donors in elderly patients. Haematologica 2006;91:852-855.

17. Koreth J, Aldridge J, Kim HT, Alyea EP, et al. Reduced intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age. Biol Blood Marrow Transplant 2010;16:792-800.

18. Shapira MY, Resnick IB, Bitan M, Ackerstein A, et al. Low transplant related mortality with allogenic stem cell transplantation in elderly patients. Bone Marrow Transplantation 2004;34:155-159.